BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The first analysis of the first-in-human phase 1 trial (cutoff, September 1, 2017; median follow-up, 14 months) established the safety and tolerability of asciminib in heavily pretreated patients with CML in chronic phase (CP) or accelerated phase (AP) with or without BCR::ABL1T315I [30].